RUMORED BUZZ ON CONOLIDINE PROLEVIATE FOR JOINT PAIN TREATMENT

Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Developments review discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR